File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1038/onc.2009.332
- Scopus: eid_2-s2.0-75149159101
- PMID: 19881551
- WOS: WOS:000273793200013
- Find via
Supplementary
-
Bookmarks:
- CiteULike: 1
- Citations:
- Appears in Collections:
Article: Warburg effect revisited: An epigenetic link between glycolysis and gastric carcinogenesis
Title | Warburg effect revisited: An epigenetic link between glycolysis and gastric carcinogenesis | ||||||
---|---|---|---|---|---|---|---|
Authors | |||||||
Keywords | Gastric cancer Glucose metabolism Methylation Ras | ||||||
Issue Date | 2010 | ||||||
Publisher | Nature Publishing Group. The Journal's web site is located at http://www.nature.com/onc | ||||||
Citation | Oncogene, 2010, v. 29 n. 3, p. 442-450 How to Cite? | ||||||
Abstract | In cancer cells, glucose is often converted into lactic acid, which is known as the 'Warburg effect'. The reason that cancer cells have a higher rate of aerobic glycolysis, but not oxidative phosphorylation, remains largely unclear. Herein, we proposed an epigenetic mechanism of the Warburg effect. Fructose-1,6-bisphosphatase-1 (FBP1), which functions to antagonize glycolysis was downregulated through NF-kappaB pathway in Ras-transformed NIH3T3 cells. Restoration of FBP1 expression suppressed anchorage-independent growth, indicating the relevance of FBP1 downregulation in carcinogenesis. Indeed, FBP1 was downregulated in gastric carcinomas (P<0.01, n=22) and gastric cancer cell lines (57%, 4/7). Restoration of FBP1 expression reduced growth and glycolysis in gastric cancer cells. Moreover, FBP1 downregulation was reversed by pharmacological demethylation. Its promoter was hypermethylated in gastric cancer cell lines (57%, 4/7) and gastric carcinomas (33%, 33/101). Inhibition of NF-kappaB restored FBP1 expression, partially through demethylation of FBP1 promoter. Notably, Cox regression analysis revealed FBP1 promoter methylation as an independent prognosis predicator for gastric cancer (hazard ratio: 3.60, P=0.010). In summary, we found that NF-kappaB functions downstream of Ras to promote epigenetic downregulation of FBP1. Promoter methylation of FBP1 can be used as a new biomarker for prognosis prediction of gastric cancer. Such an important epigenetic link between glycolysis and carcinogenesis partly explains the Warburg effect. © 2010 Macmillan Publishers Limited All rights reserved. | ||||||
Persistent Identifier | http://hdl.handle.net/10722/142538 | ||||||
ISSN | 2023 Impact Factor: 6.9 2023 SCImago Journal Rankings: 2.334 | ||||||
ISI Accession Number ID |
Funding Information: The project was supported by RGC-GRF ( Project No. 465808) granted to HJ, and Research Funding from the Institute of Digestive Disease, the Chinese University of Hong Kong. |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Liu, X | en_US |
dc.contributor.author | Wang, X | en_US |
dc.contributor.author | Zhang, J | en_US |
dc.contributor.author | Lam, EKY | en_US |
dc.contributor.author | Shin, VY | en_US |
dc.contributor.author | Cheng, ASL | en_US |
dc.contributor.author | Yu, J | en_US |
dc.contributor.author | Chan, FKL | en_US |
dc.contributor.author | Sung, JJY | en_US |
dc.contributor.author | Jin, HC | en_US |
dc.date.accessioned | 2011-10-28T02:50:46Z | - |
dc.date.available | 2011-10-28T02:50:46Z | - |
dc.date.issued | 2010 | en_US |
dc.identifier.citation | Oncogene, 2010, v. 29 n. 3, p. 442-450 | en_US |
dc.identifier.issn | 0950-9232 | - |
dc.identifier.uri | http://hdl.handle.net/10722/142538 | - |
dc.description.abstract | In cancer cells, glucose is often converted into lactic acid, which is known as the 'Warburg effect'. The reason that cancer cells have a higher rate of aerobic glycolysis, but not oxidative phosphorylation, remains largely unclear. Herein, we proposed an epigenetic mechanism of the Warburg effect. Fructose-1,6-bisphosphatase-1 (FBP1), which functions to antagonize glycolysis was downregulated through NF-kappaB pathway in Ras-transformed NIH3T3 cells. Restoration of FBP1 expression suppressed anchorage-independent growth, indicating the relevance of FBP1 downregulation in carcinogenesis. Indeed, FBP1 was downregulated in gastric carcinomas (P<0.01, n=22) and gastric cancer cell lines (57%, 4/7). Restoration of FBP1 expression reduced growth and glycolysis in gastric cancer cells. Moreover, FBP1 downregulation was reversed by pharmacological demethylation. Its promoter was hypermethylated in gastric cancer cell lines (57%, 4/7) and gastric carcinomas (33%, 33/101). Inhibition of NF-kappaB restored FBP1 expression, partially through demethylation of FBP1 promoter. Notably, Cox regression analysis revealed FBP1 promoter methylation as an independent prognosis predicator for gastric cancer (hazard ratio: 3.60, P=0.010). In summary, we found that NF-kappaB functions downstream of Ras to promote epigenetic downregulation of FBP1. Promoter methylation of FBP1 can be used as a new biomarker for prognosis prediction of gastric cancer. Such an important epigenetic link between glycolysis and carcinogenesis partly explains the Warburg effect. © 2010 Macmillan Publishers Limited All rights reserved. | - |
dc.language | eng | en_US |
dc.publisher | Nature Publishing Group. The Journal's web site is located at http://www.nature.com/onc | - |
dc.relation.ispartof | Oncogene | en_US |
dc.subject | Gastric cancer | - |
dc.subject | Glucose metabolism | - |
dc.subject | Methylation | - |
dc.subject | Ras | - |
dc.subject.mesh | Cell Transformation, Neoplastic - genetics - metabolism | - |
dc.subject.mesh | Epigenesis, Genetic | - |
dc.subject.mesh | Fructose-Bisphosphatase - genetics - metabolism | - |
dc.subject.mesh | Glycolysis | - |
dc.subject.mesh | Stomach Neoplasms - genetics - metabolism - pathology | - |
dc.title | Warburg effect revisited: An epigenetic link between glycolysis and gastric carcinogenesis | en_US |
dc.type | Article | en_US |
dc.identifier.email | Shin, VY: vyshin@hku.hk | en_US |
dc.description.nature | link_to_OA_fulltext | - |
dc.identifier.doi | 10.1038/onc.2009.332 | - |
dc.identifier.pmid | 19881551 | - |
dc.identifier.scopus | eid_2-s2.0-75149159101 | - |
dc.identifier.hkuros | 184628 | en_US |
dc.identifier.volume | 29 | en_US |
dc.identifier.issue | 3 | en_US |
dc.identifier.spage | 442 | en_US |
dc.identifier.epage | 450 | en_US |
dc.identifier.isi | WOS:000273793200013 | - |
dc.identifier.citeulike | 6065960 | - |
dc.identifier.issnl | 0950-9232 | - |